Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib

Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib

RAPTA-EA1 is a promising glutathione transferase (GSTP-1) inhibitor that has previously been shown to inhibit the growth of various breast cancer cells. We studied the anticancer activity of RAPTA-EA1 on triple-negative BRCA1 competent breast cancer MDA-MB-231 cells. MDA-MB-231 cells are significant...

Full description

Bibliographic Details
Main Authors: Khwanjira Hongthong, Tidarat Nhukeaw, Pornvichai Temboot, Paul J. Dyson, Adisorn Ratanaphan
Format: Article
Language:English
Published: Elsevier 2021-08-01
Series:Heliyon
Subjects:
Anti-cancer drugs
Metal-based drugs
BRCA1
RAPTA-EA1
Olaparib
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844021018521

Internet

http://www.sciencedirect.com/science/article/pii/S2405844021018521

Similar Items